342 related articles for article (PubMed ID: 19527097)
21. Paying a high price for low costs: why there should be no legal constraints on the profits that can be made on drugs for tropical diseases.
Sonderholm J
J Med Ethics; 2009 May; 35(5):315-9. PubMed ID: 19407038
[TBL] [Abstract][Full Text] [Related]
22. Does reimportation reduce price differences for prescription drugs? Lessons from the European Union.
Kyle MK; Allsbrook JS; Schulman KA
Health Serv Res; 2008 Aug; 43(4):1308-24. PubMed ID: 18355258
[TBL] [Abstract][Full Text] [Related]
23. [Economic or medical innovations: that is the question!].
Freitag MH; Wohlgemuth WA
Med Klin (Munich); 2006 Jul; 101(7):590-1; author reply 591-3. PubMed ID: 16897896
[No Abstract] [Full Text] [Related]
24. Reimbursement for new health technologies. Breakthrough pharmaceuticals as a 20th century challenge.
Glynn D
Pharmacoeconomics; 2000; 18 Suppl 1():59-67. PubMed ID: 11151310
[TBL] [Abstract][Full Text] [Related]
25. An empirical analysis of the multimarket contact theory in pharmaceutical markets.
Coronado J; Jiménez-Martín S; Marín PL
Eur J Health Econ; 2014 Jul; 15(6):623-43. PubMed ID: 23818281
[TBL] [Abstract][Full Text] [Related]
26. International differences in drug prices.
Wagner JL; McCarthy E
Annu Rev Public Health; 2004; 25():475-95. PubMed ID: 15015931
[TBL] [Abstract][Full Text] [Related]
27. Biotech drugs: high costs becoming hard to swallow.
Wagner M
Mod Healthc; 1992 Jan; 22(2):24-5, 28-9. PubMed ID: 10115803
[TBL] [Abstract][Full Text] [Related]
28. Australian pharmaceutical policy: price control, equity, and drug innovation in Australia.
Doran E; Alexander Henry D
J Public Health Policy; 2008 Apr; 29(1):106-20. PubMed ID: 18368023
[TBL] [Abstract][Full Text] [Related]
29. Generic medicine pricing in Europe: current issues and future perspective.
Simoens S
J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
[TBL] [Abstract][Full Text] [Related]
30. Financial effects of pharmaceutical price regulation on R&D spending by EU versus US firms.
Golec J; Vernon JA
Pharmacoeconomics; 2010; 28(8):615-28. PubMed ID: 20617857
[TBL] [Abstract][Full Text] [Related]
31. Market watch: sales trends by therapeutic area: 2008-2013E.
Goodman M
Nat Rev Drug Discov; 2009 Sep; 8(9):689. PubMed ID: 19721440
[No Abstract] [Full Text] [Related]
32. Estimating the market for tuberculosis drugs in industrialized and developing nations.
Schwalbe NR; Wells WA; Geaneotes AP; Forcellina A; Lee MG; Dicola L; Ignatius HR; Walker CL; Raafat T; Patel N
Int J Tuberc Lung Dis; 2008 Oct; 12(10):1173-81. PubMed ID: 18812048
[TBL] [Abstract][Full Text] [Related]
33. Excessive pricing in the pharmaceutical industry: adding another string to the bow of EU competition law.
Danieli D
Health Econ Policy Law; 2021 Jan; 16(1):64-75. PubMed ID: 32434612
[TBL] [Abstract][Full Text] [Related]
34. Trade talks between US and EU could increase cost of drugs, new report says.
Cohen D
BMJ; 2014 Mar; 348():g2402. PubMed ID: 24671989
[No Abstract] [Full Text] [Related]
35. Drug pricing. AHF presses for indemnification over Norvir price increase.
AIDS Policy Law; 2004 Feb; 19(4):2. PubMed ID: 15045980
[No Abstract] [Full Text] [Related]
36. [European ordinance on orphan drugs: changes and threats].
Linthorst GE; Hollak CE
Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543
[TBL] [Abstract][Full Text] [Related]
37. What future does the pharmaceutical industry have in the cardiovascular world?
Braunwald E
Eur Heart J; 2013 Apr; 34(13):943-4. PubMed ID: 23546415
[No Abstract] [Full Text] [Related]
38. Medicinal products in the European Union--between harmonization and divergence.
Lojko N
Med Law; 2010 Mar; 29(1):61-76. PubMed ID: 22457998
[TBL] [Abstract][Full Text] [Related]
39. Antibiotic development: a victim of market forces?
Tillotson GS
IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
[TBL] [Abstract][Full Text] [Related]
40. Monitoring the price of new drugs.
Silversides A
CMAJ; 2006 May; 174(11):1548-9. PubMed ID: 16717260
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
